Literature DB >> 17166998

Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study.

Robert James Cerfolio1, Ayesha S Bryant, Mohamad A Eloubeidi.   

Abstract

BACKGROUND: Despite normal mediastinal (N2) lymph nodes shown on positron emission tomography (PET) and CT, some physicians routinely perform mediastinoscopy and/or endoscopic ultrasound fine-needle aspiration (EUS-FNA) in patients with non-small cell lung cancer (NSCLC).
METHODS: A prospective trial on patients with NSCLC who were clinically staged N2 negative by both integrated PET/CT and CT scan. All underwent mediastinoscopy and EUS-FNA and if N2 negative underwent thoracotomy with thoracic lymphadenectomy.
RESULTS: There were 153 patients (107 men). Of these, 136 patients were clinically staged N0 and 17 patients were clinically staged N1. Of the 136 patients who were staged as N0, 5 patients (3.7%) had positive EUS-FNA results (three in the subcarinal node), and 4 patients (2.9%) had positive mediastinoscopy results (all in the #4R node; one was N3). Six of the remaining 127 patients (4.7%) had N2 disease after resection. Seventeen patients were clinically staged as N1 by integrated PET/CT. Four patients (23.5%) had positive EUS-FNA results (two in the subcarinal node), 3 patients (17.6%) had positive mediastinoscopy results (all in #4R node; two were N2 and one was N3), and none of the remaining 10 patients had N2 disease after resection. Patients with unsuspected N2 disease were twice as likely (relative risk, 2.1; 95% confidence interval, 1.24 to 2.51; p = 0.02) to have a maximum standardized uptake value (maxSUV) > 10 and poorly differentiated cancer (relative risk, 2.1; 95% confidence interval, 1.14 to 2.38; p = 0.03).
CONCLUSION: We do not recommend routine mediastinoscopy or EUS-FNA in patients who are clinically staged as N0 after both integrated PET/CT and CT. However, these procedures should both be considered in patients clinically staged as N1 after PET/CT, and/or in those with adenocarcinoma, upper-lobe tumors, or tumors with a maxSUV > or = 10.

Entities:  

Mesh:

Year:  2006        PMID: 17166998     DOI: 10.1378/chest.130.6.1791

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  33 in total

1.  Invasive mediastinal staging of non-small-cell lung cancer: a clinical practice guideline.

Authors:  G E Darling; A J Dickie; R A Malthaner; E B Kennedy; R Tey
Journal:  Curr Oncol       Date:  2011-12       Impact factor: 3.677

Review 2.  [Role of mediastinoscopy and repeat mediastinoscopy today].

Authors:  M Hinterthaner; G Stamatis
Journal:  Chirurg       Date:  2008-01       Impact factor: 0.955

3.  Determinants of practice patterns and quality gaps in lung cancer staging and diagnosis.

Authors:  David E Ost; Jiangong Niu; Linda S Elting; Thomas A Buchholz; Sharon H Giordano
Journal:  Chest       Date:  2014-05       Impact factor: 9.410

Review 4.  Clinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer.

Authors:  Poul Henning Madsen; Paw Christian Holdgaard; Janne Buck Christensen; Poul Flemming Høilund-Carlsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-11       Impact factor: 9.236

5.  Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis.

Authors:  Jingbo Wang; Kathy Welch; Luhua Wang; Feng-Ming Spring Kong
Journal:  Clin Lung Cancer       Date:  2011-11-03       Impact factor: 4.785

6.  Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non-Small Cell Lung Cancer.

Authors:  Paul J Speicher; Zachary W Fitch; Brian C Gulack; Chi-Fu J Yang; Betty C Tong; David H Harpole; Thomas A D'Amico; Mark F Berry; Matthew G Hartwig
Journal:  Ann Thorac Surg       Date:  2016-07-29       Impact factor: 4.330

7.  A Prediction Model to Help with the Assessment of Adenopathy in Lung Cancer: HAL.

Authors:  Oisin J O'Connell; Francisco A Almeida; Michael J Simoff; Lonny Yarmus; Ray Lazarus; Benjamin Young; Yu Chen; Roy Semaan; Timothy M Saettele; Joseph Cicenia; Harmeet Bedi; Corrine Kliment; Liang Li; Sonali Sethi; Javier Diaz-Mendoza; David Feller-Kopman; Juhee Song; Thomas Gildea; Hans Lee; Horiana B Grosu; Michael Machuzak; Macarena Rodriguez-Vial; George A Eapen; Carlos A Jimenez; Roberto F Casal; David E Ost
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

8.  Quality gaps and comparative effectiveness in lung cancer staging and diagnosis.

Authors:  David E Ost; Jiangong Niu; Linda S Elting; Thomas A Buchholz; Sharon H Giordano
Journal:  Chest       Date:  2014-02       Impact factor: 9.410

9.  N2 disease in T1 non-small cell lung cancer.

Authors:  Sebastian A Defranchi; Stephen D Cassivi; Francis C Nichols; Mark S Allen; K Robert Shen; Claude Deschamps; Dennis A Wigle
Journal:  Ann Thorac Surg       Date:  2009-09       Impact factor: 4.330

Review 10.  Post-operative radiation therapy (PORT) in completely resected non-small-cell lung cancer.

Authors:  Yelena Krupitskaya; Billy W Loo
Journal:  Curr Treat Options Oncol       Date:  2009-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.